US2014256617A1PendingUtilityA1
In Situ Forming Hydrogel and Method Using Same
Est. expiryOct 12, 2031(~5.2 yrs left)· nominal 20-yr term from priority
A61L 27/52A61L 2300/404A61K 47/32A61L 2430/24A61K 9/0024A61K 38/14A61K 9/06A61P 19/00A61L 27/54A61L 27/50A61L 2400/06
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A hydrogel (I), comprising a polymer backbone wherein an aqueous solution of the hydrogel comprises a first lower critical solution temperature, and wherein the hydrogel is configured to be converted in vivo into a modified hydrogel, and wherein an aqueous solution of the modified hydrogel comprises a second lower critical solution temperature, and wherein the second lower critical solution temperature is greater than the first lower critical solution temperature.
Claims
exact text as granted — not AI-modified1 . A hydrogel, comprising:
a polymer backbone comprising a plurality of repeat units, wherein one or more of the plurality of repeat units comprises a pendent water soluble polymer attached thereto; wherein: an aqueous solution of a polymer comprises a first lower critical solution temperature (“LCST”); said solution forms said hydrogel when heated above that first LCST; said hydrogel is configured to be converted in vivo into a modified hydrogel; an aqueous solution of said modified hydrogel comprises a second lower critical solution temperature (“LCST”); said second LCST is greater than said first LCST.
2 . (canceled)
3 . The hydrogel of claim 1 , wherein said polymer backbone comprises a terpolymer.
4 . The hydrogel of claim 3 , wherein said terpolymer comprises a second plurality of repeat units having a structure:
wherein R3 and R4 are each independently selected from the group consisting of H and alkyl.
5 . The hydrogel of claim 4 , wherein said terpolymer comprises a third plurality of repeat units having a structure:
wherein linkage R8 is selected from the group consisting of ester, amide, thioamide, thiourea, anhydride, thioester, thiourea, and alkyl;
wherein R6 is selected from the group consisting of alkyl, phenyl, polyesters, and lactones; and
wherein either R8 or R6 comprises at least one ester or anhydride.
6 . The hydrogel of claim 5 , wherein said first plurality of repeat units comprise a structure:
7 . The hydrogel of claim 5 , wherein said first plurality of repeat units comprise a structure:
8 . The hydrogel of claim 5 , wherein said first plurality of repeat units comprise a structure:
9 . The hydrogel of claim 5 , wherein said terpolymer further comprises a first plurality of repeat units having a structure:
10 . The hydrogel of claim 5 , wherein said terpolymer further comprises a first plurality of repeat units having a structure:
11 . The hydrogel of claim 5 , wherein said terpolymer further comprises a first plurality of repeat units having a structure:
12 . The hydrogel of claim 5 , wherein the water soluble polymer comprises a polyether.
13 . The hydrogel of claim 12 , wherein the polyether comprises a fourth plurality of repeat units having a structure:
14 . The hydrogel of claim 12 , wherein the polyether comprises a fourth plurality of repeat units having a structure
15 . A method to deliver a medicament in vivo, comprising:
providing a medicament and a hydrogel, wherein said hydrogel comprises a polymer with a first lower critical solution temperature (“LCST”); wherein one or more of the plurality of repeat units of said polymer comprises a pendent water soluble polymer attached thereto by a linkage selected from the group consisting of amide, thioamide, urea, thiourea, ester, and anhydride; administering at an administration site said medicament and said hydrogel into an animal, wherein said animal comprises a body temperature wherein said body temperature is greater than said LCST; releasing in vivo said medicament from said hydrogel; converting in vivo said hydrogel into a modified polymer, wherein an aqueous solution of said modified polymer comprises a second lower critical solution temperature (“LCST”), and wherein said second LCST is greater than said body temperature; excreting said modified polymer by said animal.
16 . The method of claim 15 , wherein said polymer comprises a first plurality of repeat units having a structure:
wherein R7 is selected from the group consisting of an amide linkage, a thioamide linkage, a urea linkage, a thiourea linkage, an anhydride linkage, and an ester linkage.
17 . The method of claim 16 , wherein said polymer backbone comprises a terpolymer.
18 . The method of claim 17 , wherein said terpolymer comprises a second plurality of repeat units having a structure:
wherein R3 and R4 are each independently selected from the group consisting of H, methyl, ethyl, and phenyl.
19 . The method of claim 18 , wherein said terpolymer comprises a third plurality of repeat units having a structure:
wherein linkage R8 is selected from the group consisting of ester, amide, thioamide, thiourea, anhydride, thioester, thiourea, and alkyl;
wherein R6 is selected from the group consisting of alkyl, phenyl, polyesters, and lactones; and
wherein either R8 or R6 comprises at least one ester or anhydride.
20 . The method of claim 19 , wherein said first plurality of repeat units comprise a structure:
21 . The method of claim 19 , wherein said first plurality of repeat units comprise a structure:
22 . The method of claim 19 , wherein said first plurality of repeat units comprise a structure:
23 . The method of claim 19 , wherein said first plurality of repeat units comprise a structure:
24 . The method of claim 19 , wherein said terpolymer further comprises a first plurality of repeat units having a structure:
25 . The method of claim 19 , wherein said terpolymer further comprises a first plurality of repeat units having a structure:
26 . The method of claim 16 , wherein the water soluble polymer comprises a polyether.
27 . The hydrogel of claim 26 , wherein the polyether comprises a fourth plurality of repeat units having a structure:
28 . The hydrogel of claim 26 , wherein the polyether comprises a fourth plurality of repeat units having a structure
29 . A method to administer a hydrogel in vivo to an animal to an administration site, including a human, wherein:
said hydrogel comprises a polymer; said hydrogel contains over 50% by weight of an aqueous solvent; said polymer forms physical crosslinks during the use of said hydrogel in response to an environmental condition.
30 - 41 . (canceled)
42 . The method of claim 29 , wherein said polymer forms physical crosslinks in response to a change in temperature.
43 . The method of claim 29 , wherein said administration site comprises a joint space.
44 . The method of claim 29 , wherein said administration site comprises a knee joint.
45 . The method of claim 29 , wherein said administration site comprises a hip joint.
46 . The method of claim 29 , wherein said administration site comprises a surface of an implanted medical device.
47 . The method of claim 34 , wherein said implanted medical device comprises a prosthetic joint.
48 . The method of claim 46 , wherein said implanted medical device is used in orthopaedic surgery.
49 . The method of claim 46 , wherein said hydrogel is administered to said implanted medical device after implantation of said implanted medical device
50 . The method of claim 29 , wherein said hydrogel comprises one or more medicaments.
51 . The method of claim 29 , wherein said hydrogel contains no medicament.
52 . The method of claim 29 , wherein said hydrogel comprises an antimicrobial.Join the waitlist — get patent alerts
Track US2014256617A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.